

Current Evidence on the Use of Curcumin in Modern Periodontology- A Narrative Review

Shervin Molayem*

Periodontist, Private Practice, Los Angeles, California

***Corresponding author:** Shervin Molayem, Periodontist, Private Practice, Los Angeles, California.

Citation: Molayem S. (2021) Current Evidence on the Use of Curcumin in Modern Periodontology- A Narrative Review J Oral Med and Dent Res. 2(1):1-24.

Received: February 02, 2021 | **Published:** February 23, 2021

Copyright© 2021 genesis pub by Molayem S. CC BY-NC-ND 4.0 DEED. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives 4.0 International License., This allows others distribute, remix, tweak, and build upon the work, even commercially, as long as they credit the authors for the original creation.

Abstract

Curcumin, the main bioactive ingredient in turmeric, has been used to treat multiple diseases and conditions due to its numerous health benefits and therapeutic effects. The properties of natural and chemically modified curcumin (CMC) have been extensively investigated, with strong evidence on its anti-inflammatory, anti-microbial (antibacterial, antiviral, antifungal properties), antioxidant, anti-angiogenic, anti-carcinogenic, antispasmodic, hepato-protective, and wound healing properties. The aim of this review aims to present an overview of the use of curcumin in periodontal therapy and the biological mechanisms behind its properties. Findings from in vitro studies suggest that curcumin can promote osteogenesis, down regulate proteases, promote wound healing, and suppress periodontal bacteria. Results from animal studies suggest the potential of curcumin to reduce periodontal inflammation and alveolar bone loss. Topical application of curcumin has been evaluated in clinical studies as an adjunct to periodontal therapy in the form of gel, mouthwash, irrigation solution, adhesive strip, sponge, and chip. The benefits of the topical use of curcumin have been compared to those of chlorhexidine and have been widely confirmed in pre-clinical studies. The majority of clinical studies report superior clinical and microbiological results when curcumin is used in combination with mechanical therapy. Nonetheless, there is a lack of randomized clinical trials with long-term follow-up and adequate sample

size. The low toxicity, limited side effects, availability, low cost, and a full spectrum of beneficial biological properties are among the main advantages of curcumin. Despite the major health benefits associated with the use of curcumin, more studies are warranted to further investigate its effectiveness in the management of periodontal disease.

Keywords

Curcumin; Periodontal inflammation; Alveolar bone loss; Periodontology; Metabolism; Osteoclastogenesis; Microbiological parameters

Introduction

The roots of the plant *Curcuma longa*, which belongs to the ginger family, is the source of a colorful spice, widely known as turmeric. With its distinctive taste, turmeric has long been used in culinary, particularly in South-eastern Asia cuisine, in the cosmetic and fabric dye industry. Curcumin is the main bioactive ingredient in turmeric and it has been associated with a variety of health benefits and therapeutic effects [1].

The therapeutic use of turmeric in traditional medicine dates back to ancient times, with its origins in the Indian Vedic tradition [1]. Historically, turmeric has been used in the treatment of multiple diseases and conditions, however, the first scientific report on its anti-bacterial properties was only published in 1949 [2]. The first scientific study on the use of curcumin in Dentistry was published in 1994. The authors reported the beneficial effects of dietary turmeric in oral carcinogenesis in hamsters [3].

The properties of curcumin have been extensively investigated, with strong evidence on its antibacterial, anti-inflammatory, anti-oxidant, anti-tumor, and anti-angiogenic effects. Natural curcumin is poorly absorbed in the gastrointestinal tract, which reduces its bioavailability. Due to the wide range of biological effects, safety, and lack of significant adverse effects of curcumin, there has been increasing interest in the production of synthetic analogs to improve the pharmacological characteristics of the natural compound [4].

The potential of curcumin as a therapeutic agent to help restore oral health is vast [5]. More recent studies suggest that chemically modified curcumin (CMC) has host-modulating properties, while curcumin-based gel and mouthwashes have the potential to reduce plaque, gingival inflammation, and pocket depth [6]. This narrative review aims to present an overview of the use of curcumin in periodontal therapy and the biological mechanisms behind its properties. The clinical relevance of this review lies in the need for evidence-based natural approaches to oral diseases and conditions and the potential benefits associated with this compound.

New trends- Growing Demand for Natural Products

There is a growing demand for a more integrative health approach, one that considers all factors that influence health and disease, such as genetic and environmental risk factors, lifestyle, diet, and emotional wellbeing. Integral and functional medicines are two modalities that have expanded significantly, with similar trends observed for holistic, biological, and functional dentistry. The main difference between these emerging trends and traditional medicine and dentistry is that healthcare professionals treat the patient as a whole, as opposed to treating the disease and its symptoms [6,7].

In line with more holistic approaches, there has also been increased interest in decreasing the chemical body burden, which can originate from the environment (air, water, soil, food, etc.), medications, and personal care products, among other sources [8]. Herbal and natural products play an important role in these integrative approaches, with turmeric having potent medicinal effects as a supplement and therapeutic agent for numerous diseases and conditions [5]. While herbal products are increasingly popular, their use should be based on scientific evidence. In this review, the scientific foundation for the use of curcumin in periodontology will be discussed.

Therapeutic Use of Curcumin in Medicine

A recent bibliometric analysis of the literature on curcumin found over 18,000 publications on the topic, including clinical and experimental research, in vitro studies, meta-analyses, and reviews, from which half were published after 2014. The majority of studies evaluated curcumin use in relation to cancer, inflammatory conditions, and oxidative stress. The overwhelming number of studies on this natural compound points to its promising therapeutic properties [9].

Several beneficial biological activities have been associated with curcumin, including anti-inflammatory, anti-microbial (antibacterial, antiviral, antifungal properties), antioxidant, anti-angiogenic, anti-carcinogenic, antispasmodic, hepato-protective, and wound healing properties. It affects multiple signaling molecules and cellular activities. Therefore, it has been investigated for the treatment of a variety of inflammatory conditions and tumors, through in vitro, experimental, and clinical studies (Table 1). In dentistry, curcumin has been evaluated for the treatment of oral mucosal lesions, oral cancer, and periodontal disease [10-17,5].

Respiratory system [11]	Asthma, respiratory allergy, fibrosis, bronchitis, acute lung injury
Joints [10]	Rheumatoid arthritis, osteoarthritis
Digestive system [12]	Inflammatory bowel disease, pancreatitis, Helicobacter pyloric gastric inflammation, ulcerative colitis, reflux esophagitis
Neurological system [13]	Alzheimer disease, Parkinson's disease, multiple sclerosis
Metabolic conditions [10]	Diabetes, metabolic syndrome
Hepatic	Non-alcoholic steatohepatitis, alcoholic liver disease, hepatic fibrosis, liver injury, cirrhosis,

conditions [14]	hepatotoxicit
Cardiovascular system [15]	Heart failure, cardiac hypertrophy, aortic aneurism, atherosclerosis, cardiomyopathy, myocardial infarction, stroke
Cancer [16]	Breast cancer, lung cancer, skin cancer, hematological cancers, digestive system cancers, prostate cancer, brain tumors, head and neck cancer
Skin conditions [17]	psoriasis, atopic dermatitis, iatrogenic dermatitis, wound healing, skin aging

Table 1: Medical conditions that can potentially benefit from the therapeutic use of curcumin.

Curcumin Characteristics

Turmeric has three main curcuminoids: curcumin, demethoxycurcumin, and bisdemethoxycurcumin. Also known as diferuloylmethane, curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) corresponds to 1-6% of turmeric components, being the pigment that gives its characteristic orange/yellow color [1]. In commercial turmeric powder, the average curcumin concentration is 3.1% by weight [18]. Curcumin is a polyphenol with low solubility in water, being poorly absorbed and quickly eliminated by the gastrointestinal tract in its natural state [19]. It can be found in the form of turmeric, curcuminoids, or curcumin [20].

Delivery: Agents that increase the bioavailability and bio-efficacy of curcumin have been used as delivery systems, which include micelles, microgels, liposomes, phospholipids, emulsions, lipid carriers, and biopolymer nanoparticles. Most delivery agents act by decreasing the degradation of curcumin in the gastrointestinal tract [20]. Piperine, the main active ingredient in black pepper, has also been found to increase the availability of curcumin by 2000%. Chemical modifications of curcumin have been explored as another way to enhance its bioavailability. Vehicles such as corn oil, cellulose, and carboxymethyl have been suggested to improve curcumin availability [21].

Metabolism: Curcumin's metabolism happens primarily in the liver and intestines, being further metabolized by the intestinal microbiome. After oral intake, it undergoes multiple reduction reactions, reaching peak concentration in the body after 1-2 hours [22].

Safety profile: The US Food and Drug Administration (FDA) considers curcuminoids generally safe for humans. Safety has been confirmed through numerous clinical trials, which report general good tolerance and lack of toxicity, even at high doses (4000 mg/day and above) [23]. The European Food and Safety Authority (EFSA) has suggested the acceptable daily intake (ADI) value to be and 3 mg/kg body weight for curcumin [24].

Side effects: Despite curcumin's minimal toxicity, mild side effects such as headache, diarrhea, rash, allergy, and yellow stool have been reported in a dose-escalation study. In total, 30% of the included healthy volunteers who were administered 1 to 12 g in a single oral dose presented one of those side effects [25].

Synthetic analogs: Different CMC compounds have been formulated to change its diketone form into triketone form, improving the chemical properties such as zinc-binding, bioavailability, and therapeutic effects. Some analogs include difluorinated-curcumin (CDF), dimethoxycurcumin, compound 23, GO-Y039, CMC 2.24, and EF24. Pre-clinical studies suggest stronger inhibition of matrix metalloproteinases (MMPs) for CMC, as compared to its natural form [26].

Therapeutic Use of Curcumin in Periodontology

In Vitro Studies

Multiple in vitro studies have reported the anti-inflammatory activity of curcumin and CMC. Studies on human periodontal ligament stem cells (hPDLSCs) exposed to curcumin report increased osteogenic cell differentiation and improved balance between MMPs and their tissue inhibitors [27,28]. Exposure of human gingival fibroblasts to curcumin enhanced wound healing when compared to CHX exposure [29]. Gingival tissues from periodontitis patients presented comparable MMP-9 decrease when exposed to curcumin or doxycycline [30]. The antimicrobial capacity of curcumin has also been reported in studies on periodontal bacteria, including *Porphyromonas gingivalis* (Pg), *Aggregatibacter actinomycetemcomitans* (Aa), and *Fusobacterium nucleatum* (Fn). Even with concentration as low as 12 µg/ml, curcumin was able to decrease bacterial metabolic activity, adhesion and biofilm formation in vitro when used alone or as part of photodynamic therapy (PDT) [31-37]. In human gingival fibroblasts and macrophages exposed to Pg LPS, curcumin reduced inflammatory cytokines and cyclooxygenase-2 (COX-2) expression [34-36,38]. Hu et al. [39,40] have suggested the Nuclear factor-κB (NF-κB) pathway as another potential mechanism through which curcumin can affect the initial steps of periodontitis development [40].

Animal Studies

Results from numerous experimental periodontitis studies confirm the findings from in vitro studies and suggest beneficial effects for natural curcumin and CMC in the reduction of inflammation and alveolar bone loss (Table 2). The effects of curcumin on the alveolar bone is affected by the dose, vehicle, and animal model used in the study [41-57]. Some studies suggest that CMC is superior to the natural version in the prevention of alveolar bone loss [52,57-61].

Authors	Year	Animal Model	Mode of Administration	Results
Ghavimi et al. [61]	2020	Dog	Curcumin and aspirin membrane	Curcumin and aspirin membrane increased osteogenic potential, can be beneficial to GBR
Ay et al. [45]	2020	Rat	Oral gavage (30 mg/kg/day) for 15 days	Curcumin decreased IL-1β and IL-6 mRNA expression in gingival tissues
Wang et al. [57]	2019	Rat	Oral gavage (30 mg/kg/day) for 14 days	CMC 2.24 decreased alveolar bone loss by 80%-90%, curcumin did not inhibit alveolar bone loss
Deng et al. [46]	2020	Dog	Oral CMC2.24 capsule daily for 3 months	CMC 2.24 improved clinical parameters, inflammation and alveolar bone loss compared to placebo, besides reducing MMP-9, MMP-2 in gingival tissue, and GCF IL-1β

Pimentel et al. [51]	2020	Rat	Oral gavage for 30 days	In diabetic rats, natural curcumin and insulin reduced alveolar bone loss and positively modulated immune-inflammatory mediators
Guimaraes-Stabili et al. [52]	2019	Rat	Oral gavage for 15 days	Curcumin increased early bone repair; Curcumin + piperine improved collagen repair, and decreased activation of NF- κ B in gingival tissues
Brandao et al. [52]	2018	Rat	Oral gavage 0, 1, 3, 10, and 30 mg/kg/day for 28 days	Low doses of CMC2.24 (1 mg/kg/day) significantly reduced alveolar bone resorption
Akpinar et al. [41]	2017	Rat	Gastric gavage 75 and 150 mg/kg/day	Systemic curcumin reduced alveolar bone loss in experimental periodontitis
Xiao et al. [43]	2018	Rat	Oral gavage every 2 days	Curcumin reduced gingival inflammation and alveolar bone loss, and modulated collagen fibers.
Zambrano et al. [48]	2018	Rat	Curcumin-loaded nanoparticles injection	Curcumin inhibited bone resorption, decreased osteoclast and the inflammatory infiltrate
Curylofo-Zotti et al. [58]	2018	Rat	Oral intubation curcumin or CMC2.24 30 and 100 mg/kg/day for 15 days	CMC2.24 reduced alveolar bone resorption in LPS-induced periodontitis
Theodoro et al. [49]	2017	Rat	Curcumin solution +/- LED for 30 days	PDT using curcumin and LED effectively treated induced periodontitis
Elburki et al. [53]	2017	Rat	Oral gavage CMC 2.24	CMC 2.24 reduced gingival inflammatory cytokines and MMPs, alveolar bone loss, activation of p65 (NF- κ B) and p38 MAPK
Elburki et al. [54]	2017	Rat	Oral gavage CMC 2.25	In rats with diabetes and periodontitis, CMC 2.24 reduced inflammation, hyperglycemia and connective tissue destruction
Bakir et al. [59]	2020	Rat	Oral gavage (30 mg/kg/d) for 15 days	Curcumin presented positive host modulation properties and decreased alveolar bone loss in experimental periodontitis
Correa et al. [51]	2020	Rat	Oral gavage 100 mg/kg/day curcumin for 30 days	Curcumin combined or not with resveratrol decreases alveolar bone loss in experimental periodontitis
Hosadurga et al. [60]	2014	Rat	Topical application 2% gel every second day for 6 days	Curcumin improved inflammation and inhibited 43% of edema
Elburki et al. [26]	2014	Rat	Oral intubation with CMC 2.24 for 2 weeks	CMC 2.24 decrease inflammation and alveolar bone loss in experimental periodontitis
Hu et al. [40]	2013	Rat	CMC 2.5 oral gavage 1 mL suspension 100 mg/kg	In diabetic rats, CMC reduced local and systemic inflammation and prevented tissue destruction
Zhou et al. [44]	2013	Rat	Oral gavage (100 mg/kg/day) for 30 days	Curcumin reduced ligature-induced periodontitis alveolar bone loss via suppression of RANKL/RANK/OPG
Guimaraes et al. [55]	2011	Rat	Gastric gavage 30 and 100 mg/kg/day for 15	Curcumin did not prevent alveolar bone loss in ligature-induced periodontitis

			days	
Guimaraes et al. [47]	2019	Rat	Oral gavage 30 and 100 mg/kg/day for 15 days	Curcumin reduced the inflammatory infiltrate and elevated collagen content in LPS-induced periodontitis
Mau et al. [56]	2016	Rat	Gastric gavage 30 and 100 mg/kg/day for 14 days	Curcumin inhibited inflammatory marker production and osteoclastogenesis, decreasing alveolar bone loss.

Table 2: Experimental studies on the use of curcumin in periodontology.

GBR: Guided Bone Regeneration; PDT: Photodynamic Therapy, CMC: Chemically Modified Curcumin.

In the study from Elburki et al. [54], oral administration of CMC 2.24 led to lower gingival levels of MMP and inflammatory cytokines, and reduced activation of NF- κ B and p38 MAPK. In diabetic rats with periodontitis, CMC 2.24 reduced hyperglycemia, inflammation, and connective tissue destruction [54]. In a recent systematic review and meta-analysis on the use of curcumin in experimental periodontitis, Borges et al. [21] reported that oral administration of 30mg/kg/day of CMC for at least 15 days was able to reduce periodontal bone loss. When natural curcumin was used, the 30mg/kg/day dose did not affect bone loss while the 100mg/kg/day dose led to less bone destruction, as compared to the control group [21].

The mechanisms behind the anti-inflammatory effects of curcumin and CMC in experimental periodontitis includes decreased expression of MMPs, inflammatory cytokines, such as TNF- α , IL-6 and IL-1 β mRNA in gingival tissues, and osteoclastogenesis markers, such as RANK and RANKL [44,56,59].

While most experimental studies on periodontitis and curcumin used oral or gastric gavage, Hosadurga et al. [60] investigated the topical application of curcumin gel in experimental periodontitis in rats in comparison to placebo. Gingival inflammation and edema were significantly lower in the test group [60]. More recently, the use of a collagen curcumin membrane infused with aspirin and curcumin was tested on bone defects in dogs. In defects where the test membrane was used, there was an increase in osteogenesis when compared to defects covered with a commercial membrane. The authors suggested that the antimicrobial and anti-inflammatory properties of curcumin can improve the results of guided bone regeneration procedures [61].

Clinical Studies-Topical Curcumin

Topical application of curcumin has been evaluated as an adjunct to periodontal therapy for gingivitis and chronic periodontitis in the form of gel, mouthwash, irrigation solution, adhesive strip, sponge, and chip (Table 3). Curcumin gel has been the most studied delivery method in clinical periodontal studies [62-84].

Authors	Year	Sample	Diagnosis	Mode of Administration	Groups	Duration	Parameters	Results
---------	------	--------	-----------	------------------------	--------	----------	------------	---------

Guimaraes et al. [55]	2011	n=100	Gingivitis	Mouthwash, 2x/day	A - CHX	21 days	PI, GI, bacterial count	Comparable GI and bacterial count; PI better for CHX
					B - curcumin			
Mali et al. [73]	2012	n=60	Gingivitis	Mouthwash, 2x/day	A - CHX	21 days	PI, GI, bacterial count	Comparable for all parameters
					B - curcumin			
Muglikar et al. [74]	2013	n=30	Gingivitis	Mouthwash, 2x/day	1 - SRP + CHX	21 days	PI, GI	Comparable for all parameters
					2 - SRP + curcumin			
					3- SRP			
Chatterjee et al. [72]	2017	n=50	Gingivitis	Mouthwash, 2x/day	A - curcumin	28 days	PI, GI, BOP	Comparable for all parameters
					B - placebo			
					C- CHX			
Arunachalam et al. [75]	2017	n=30	Gingivitis	Mouthwash, 2x/day	I - saline	28 days	PI, GI, salivary ROM	Comparable reduction in PI, GI; ROM reduction higher in curcumin group
					II - CHX			
					III - curcumin			
Singh et al. [82]	2015	n=40	Gingivitis	Gel, 2x/day	A - CHX	21 days	PI, GI and SBI	Better clinical outcomes in curcumin group.
					B - curcumin			
Kandwal et al. [63]	2015	n=60	Gingivitis	Gel, 2x/day	A - curcumin	21 days	PI, GI	Comparable for all parameters
					B - CHX			
Pulikkotil et al. [64]	2015	n=40	Gingivitis	Gel, 2x/day	I - CHX + metronidazole	29 days	PI, GI, BOP, PD, IL-1 β and CCL28 in GCF	Comparable for most parameters. Higher levels

					II - CHX III - curcumin and CHX			of IL-1 β and CCL28 in CHX group
Jaswal et al. [68]	2014	n=100	Gingivitis	Gel	1-arm study oral daily gel	21 days	PBI	Curcumin was effective at reducing gingival inflammation
Kaur et al. [84]	2017	n=60	Gingivitis	Capsules 350mg/day	I - SRP + curcumin II - SRP	21 days	PI, GI, PPD	Better clinical results in the curcumin group
Malekzadeh et al. [83]	2020	n=48	Gingivitis and periodontitis	Capsules 80mg 1x/day	A - Nano curcumin B - placebo	28 days	MGI, PBI, PI	PBI, MGI higher in placebo group; PI comparable
Guru et al. [30]	2017	n=45	Chronic periodontitis	Gel	1 - SRP 2 - SRP + nano curcumin 3 - SRP + CHX	45 days	BOP, PPD, CAL, bacterial count	Comparable results for curcumin and CHX, which were better than SRP alone.
Siddharth et al. [67]	2020	n=25	Chronic periodontitis	Gel	Test - SRP + curcumin Control - - SRP + CHX	3 months	SBI, PPD, relative AL, bacterial count	Curcumin group presented better results for SBI, PPD, relative AL, and CFUs than CHX group

Meghana et al. [69]	2020	n=20	Chronic periodontitis, flap surgery	Gel	A - curcumin gel postop	7 days	Tissue response, early wound healing, pain	Comparable results for most outcomes. Curcumin group used less analgesics after surgery
					B - Coe pak			
Anusha et al. [76]	2019	n=10	Chronic periodontitis	Gel	Test - SRP + curcumin	28 days	PI, GI, PPD, CAL	Reduction in PI and PPD greater in test group
					Control - SRP			
Kaur et al. [84]	2019	n=30	Chronic periodontitis	Gel	Test - SRP + curcumin	6 months	PI, GI, PPD, CAL, salivary IL-1 β	No differences between groups
					Control - SRP + CHX			
Guru et al. [30]	2017	n=25	Chronic periodontitis	Gel	1) SRP + curcumin	30 days	PI, PPD, CAL	Superior results for curcumin group
					2) SRP + ornidazole			
Pulido et al. [10]	2016	n=30	Chronic periodontitis	Gel	Test - SRP + curcumin	45 days	PI, GI, SBI, PPD	Higher reduction in clinical parameters observed in curcumin group
					Control - SRP			
Singh et al. [62]	2015	n=30	Chronic periodontitis	Gel	1) SRP + curcumin	30 days	PPD, CAL, CFU	Superior results for curcumin group
					2) SRP + CHX			

Shahzad et al. [38]	2015	n=30	Chronic periodontitis	Gel	I - SRP	28 days	PI, GI, PPD, CAL, bacterial count	The test group presented a more pronounced improvement in clinical and bacterial parameters
					II - SRP + gel			
Kandwal et al. [63]	2015	n=30	Chronic periodontitis	Gel	Test - SRP + curcumin + periodontal pack	45 days	PI, GI, PPD, CAL	No significant differences between groups
					Control - SRP + periodontal pack			
Elburki et al. [26]	2014	n=25	Chronic periodontitis	Gel	Test - SRP + gel	6 months	PI, BI, PPD, CAL, microbiological count	Lower microbiological count for periodontal bacteria was observed for curcumin group.
					Control - SRP			
Jaswal et al. [68]	2014	n=15	Chronic periodontitis	Gel	I - SRP + CHX	45 days	PI, GI, PPD, CAL	Curcumin and CHX presented comparable clinical improvement
					II - SRP + curcumin			
					III - SRP			
Behal et al. [65]	2011	n=30	Chronic periodontitis	Gel	Test - SRP + curcumin	46 days	PI, GI, SBI, PPD, RAL, trypsin-like activity	Greater improvement was observed for the test group
					Control - SRP			

Sreedhar et al. [70]	2015	n=15	Chronic periodontitis	Gel	Quadrant 1: SRP	21 days	BOP, PPD, CAL, SBI, bacterial culture	Quadrants 3 and 4 tended to have better results for all parameters.
					Quadrant 2: SRP + curcumin gel application for 5 min			
					Quadrant 3: SRP + curcumin gel application for 5 min + PDT day			
					Quadrant 4: SRP + curcumin gel + PDT day 0, 7, 21			
Mohammad CA. [71]	2020	n=90	Chronic periodontitis	Gel	A - SRP + curcumin gel + Coe pak		PI, GI, BOP, PPD, CAL, serum levels of zinc, copper, magnesium, IL-1 β , and TNF- α	Curcumin gel led to higher reduction of IL-1 β , TNF- α , copper, and clinical parameters and increase of zinc and magnesium
					B - SRP + Coe pak			
Ivanaga et al. [79]	2019	n=25	Chronic periodontitis and diabetes	Irrigation solution	1) SRP	6 months	PDD, BOP, CAL, GR, PI	SRP + PDT using curcumin and LED irradiation led to higher CAL gain in residual
					2) SRP + curcumin irrigation			

					3) SRP + LED			pockets in diabetic patients
					4) SRP + irrigation + LED			
Gottumukkala et al. [77]	2013	n=23	Chronic periodontitis	Irrigation solution	I - SRP + CHX	6 months	Redness, PI, PPD, microbiological parameters	Modest benefit of curcumin irrigation when compared to CHX
				II - SRP + curcumin				
				III - SRP				
Guimaraes et al. [47]	2019	n=60	Chronic periodontitis	Irrigation solution	I - SRP + CHX	2 months	PI, GI, PPD, microbiological parameters	CHX showed highest improvement in clinical outcomes. No differences for microbiological parameters
				II - SRP + curcumin				
				III - SRP				
Perez-Pacheco et al. [78]	2020	n=20	Chronic periodontitis	Irrigation solution	I - SRP + nanoparticles 50 µg curcumin	180 days	BOP, PPD, CAL, GCF IL-1α, IL-6, TNFα, and IL-10, bacterial count	Comparable results, no benefits for curcumin group
				II - SRP + empty nanoparticles				
Anusha et al. [76]	2019	n=45	Chronic periodontitis and RA	Mouthwash	A - SRP + CHX	6 weeks	PI, CAL, PPD, RA disease activity	Highest PI and RA parameters seen in curcumin group; highest

					B - SRP + curcumin/es sential oils			reduction PPD and CAL seen in CHX group.
					B - SRP			
Anil et al. [80]	2019	n=15	Moderate or advanced periodontitis requiring surgery	Strip	Test - curcumin mucoadhesi ve film	7 days	Healing, pain	Significantly lesser pain in curcumin group, more analgesics consumed in control group
					Control - placebo mucoadhesi ve film			
Mau et al. [56]	2016	n=20	Chronic periodontitis	Strip	I - SRP	21 days	GCF SOD	Lower levels of SOD detected in curcumin treated sites
					II - SRP + curcumin strip			
Gottumukkala et al. [81]	2014	n=60	Chronic periodontitis	Collagen sponge	I - SRP + CHX chip	6 months	PI, GI, PPD, CAL, bacterial count	CHX presented superior results for all parameters
					II - SRP + curcumin in collagen			
Singh et al. [82]	2018	n=40	Chronic periodontitis	Chip	A - SRP + CHX chip	3 months	PI, GI, PPD, RAL	Comparable results for CHX and curcumin chip, which were superior to control group
					B - SRP + curcumin chip			
					C - SRP			

Table 3: Clinical studies on the use of curcumin in periodontology.

PI: Plaque Index; GI: Gingival Index; PPD: Pocket Probing Depth; CAL: Clinical Attachment Level; RAL: Relative Attachment Level; GCF: Gingival Crevicular Fluid; GR: Gingival Recession; BOP: Bleeding On Probing; SBI: Sulcus Bleeding Index; SOD: Superoxide Dismutase; ROM: Reactive Oxygen Metabolites; RA: Rheumatoid Arthritis; CHX:

Chlorhexidine; PDT: Photodynamic Therapy.

Gel: In studies comparing the application of curcumin gel to CHX gel in gingivitis patients (applied twice a day for 21 days), curcumin was at least as effective as CHX in improving plaque index, gingiva index, and bleeding on probing. Pulikkotil & Nath [62,63] assigned sixty volunteers with healthy gingiva to one of three groups: curcumin gel, CHX gel, or CHX/metronidazole (MTZ) gel. Participants did not perform any oral hygiene apart from the oral application of the gel twice a day for 10 minutes for the duration of the study (29 days). The curcumin group presented the lowest increase in GCF (IL-1 β and chemokine ligand 28- CCL28), while the clinical variables were similar for all three groups. The authors concluded that the anti-inflammatory effect of curcumin gel was comparable to CHX-MTZ gel and superior to CHX gel [64].

The first study to investigate the use of sub-gingival curcumin gel as an adjunct to periodontitis treatment was published in 2011. Through a split-mouth design, control sites were subjected to Scaling and Root Planning (SRP) and 2% turmeric gel, while control sites were subjected to SRP alone [65]. Both groups exhibited improved outcomes for clinical parameters and trypsin-like enzyme activity, but greater reductions were observed in sites treated with curcumin gel. For pocket depth, test sites presented a 1.1 mm higher average reduction than control sites. Since then, numerous studies have further investigated the use of curcumin gel in periodontitis patients and the majority provides evidence of better clinical and microbiological outcomes when compared to placebo or SRP alone (Table 3) [65]. For the studies that provide a comparison between curcumin and CHX gel, curcumin gel performed equally or better than CHX [66-68].

Recently, the postoperative application of curcumin gel was compared to periodontal dressing application after flap surgery in twenty patients. Early wound healing and tissue response were similar in both groups, however, the curcumin group reported less use of analgesics after surgery [69]. Using a split-mouth design, Sreedar et al. [70] compared four groups: SRP, SRP + Curcumin gel, SRP + gel + PDT at day 0, SRP + gel + PDT at days 0, 7 and 21. Quadrants that were subjected to curcumin gel and photoactivation presented superior clinical results than SRP alone or combined with curcumin gel [70].

Muhammad (2020) [71] reported higher reduction of serum IL-1 β , and TNF- α and increased serum levels of zinc and magnesium when SRP was combined with curcumin gel in chronic periodontitis patients [71].

Mouthwash: In a randomized controlled trial of patients with moderate to severe gingivitis, one session of professional prophylaxis followed by twice-daily curcumin mouthwash use presented comparable results to CHX mouthwash for gingival and plaque index, when used for 14 and 28 days. These findings were supported by additional studies by additional gingivitis studies [72]. In addition to beneficial clinical results, Arunachalam et al. (2018) [75] also reported lower levels of salivary reactive oxygen metabolites (ROM) after use of curcumin oral rinse in gingivitis, which was not observed for CHX oral rinse [74,75].

In chronic periodontitis patients with rheumatoid arthritis, the effect of SRP alone or combined with CHX or curcumin/essential oils mouthwash was investigated. While the CHX group presented a higher

reduction in PPD and CAL, only the curcumin group had improvement in markers of rheumatoid arthritis [76].

Irrigation solution: The use of 1% curcumin solution as an irrigation solution for periodontal pockets in combination with SRP has been reported in the literature. Gottummukkala et al. (2013) [77] compared SRP alone, SRP combined with CHX solution or curcumin solution in the treatment of chronic periodontitis. Subgingival irrigation took place at baseline and at follow-up after 7, 14, and 21 days. Clinical parameters showed a slight benefit of curcumin in relation to CHX after 3 months, however, after 6 months, greater pocket depth reduction was observed in the CHX group. There were no differences in the BANA microbiological test results during the study. The authors concluded that, due to the lower toxicity and fewer side effects, irrigation with a curcumin solution can be an adequate substitute for CHX solution. In the study from Perez-Pacheco et al. (2020) [77] nano curcumin particles were used as an irrigation solution during SRP for the treatment of periodontitis. When compared to a placebo, the curcumin group did not present any clinical nor microbiological benefit. In type 2 diabetic patients with residual periodontal pockets, the combination of SRP and PDT using curcumin and LED irradiation showed the most positive results when compared to SRP alone, combined with curcumin irrigation or LED irradiation after 3 months [78,79].

Strip: Postoperative use of a mucoadhesive curcumin strip was evaluated after periodontal surgery in 15 patients. In each patient, control sites received a placebo strip and test sites received the curcumin strip. Healing was uneventful for all areas. After 7 days, significantly lesser pain was reported for sites that received the strip [80].

Sponge: A collagen sponge was tested for local drug delivery of curcumin in sites with pocket depth of 5 mm or more in sixty chronic periodontitis patients subjected to SRP. Control sites received CHX chips, and clinical and microbiological parameters were evaluated after 3 and 6 months. Greater results were observed for the CHX group, which can indicate the inefficacy of this delivery method for curcumin [81].

Chip: Local drug delivery using CHX or curcumin chip was compared to SRP alone in forty chronic periodontitis patients using a split-mouth design. After 3 months, CHX and curcumin sites exhibited superior clinical results, measured as plaque index, gingival index, pocket depth, and relative attachment level, with no differences between CHX and curcumin treatment [82].

Clinical Studies- Systemic Curcumin

Malekzadeh et al. (2020) [83] studied the effect of 80 mg curcumin capsules once a day or placebo on forty-eight patients who suffered from gingivitis or mild periodontitis. After 28 days, there was a statistically significant difference in papillary bleeding index (PBI), and modified gingival index (MGI), with better outcomes observed in the test group. After 4 weeks, all patients were subjected to SRP. In the absence of SRP, systemic curcumin presented positive effects of gingival bleeding and inflammation [83].

The effect of systemic curcumin as an adjunct to periodontal treatment in gingivitis patients was investigated by Kaur et al. [84] Sixty patients were enrolled and as randomly assigned to receive SRP or SRP combined with 350 mg of an antioxidant mixture containing curcumin, lycopene and piperine. Gingival clinical parameters were evaluated after 3 weeks and reduction in plaque index, gingival index and pocket depth were marginally higher in the test group, suggesting that adjuvant systemic antioxidants can help reduce gingival inflammation [84].

Anti-Inflammatory and Anti-Microbial Properties of Curcumin

In periodontology, the most relevant biologic activities of curcumin are related to its anti-inflammatory and antimicrobial properties. Multiple molecular mechanisms have been described to explain curcumin's anti-inflammatory actions, including:

- **Nuclear Factor Kappa (NF-κB):** this protein plays a crucial role in the cellular and molecular signaling that takes place during several chronic inflammatory diseases, including periodontitis, rheumatoid arthritis, inflammatory bowel disease, and asthma. In vitro experiments, exposure of cells to cytokines, microbial pathogens, or their products induces activation of NF-κB, which is suppressed by curcumin [85,86].
- **Cyclooxygenase-2 (COX-2):** this enzyme catalyzes the formation of prostaglandins, which are important mediators in the inflammatory response. Prostaglandins have been implicated in the pathogenesis of periodontitis and alveolar bone resorption. Curcumin has been demonstrated to inhibit COX-2 expression in vitro [87].
- **Inducible nitric oxide synthase (iNOS):** This enzyme is key for the production of nitric oxide and is regulated by NF-κB. Nitric oxide is an important signaling molecule that participates in the pathogenesis of inflammation in the lungs, joints, intestines, and gingiva [88]. Curcumin can promote degradation of iNOS and inhibit its synthesis [89].
- **Vascular endothelial cell surface adhesion molecules:** including E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular adhesion molecule-1 (VCAM-1). Expression of these adhesion proteins in the endothelium is mediated by pro-inflammatory cytokines and NF-κB, resulting in the extravasation of leukocytes from the blood vessels into the tissues [90]. Curcumin down regulates expression of vascular adhesion proteins by inhibiting NF-κB [91].
- **Cytokines:** Curcumin has been demonstrated to regulate the expression of multiple pro-inflammatory cytokines, such as IL-1β, IL-2, IL-5, IL-6, IL-8, IL-12, IL-18, and TNF-α. Those molecules are crucial components of the tissue destruction process in periodontal disease [92].
- **AP-1 transcription factor:** curcumin has been shown to inhibit this protein, which regulates a variety of cellular responses through gene expression, such as proliferation and apoptosis. Regulation of AP-1 indirectly affects the production of iNOS, cytokines, and matrix metalloproteinases (MMPs) [85].
- **MMPs:** these endopeptidases degrade extracellular and membrane components, including collagen, and mediate periodontal destruction. MMP-1, 3, 9, 14, and 13 secretion can be inhibited by curcumin [92].

- **Anti-oxidant:** curcumin is a potent scavenger for free radical compounds, including reactive oxygen species. It also inhibits the generation of free radicals and lipid peroxidation. These actions contribute to the reduction of oxidative stress [93].
- **Cytoprotective proteins:** the potential of curcumin to stimulate the expression of cytoprotective proteins, such as catalase, glutathiones, and superoxide dismutase, which indirectly decrease oxidative stress [93].

The anti-microbial activity of curcumin has been attributed to its effect reducing microbial cell division, inhibition of virulence factors, damage to the microbial membrane, prevention of microbial adhesion to host cells, and consequent reduction in biofilm formation [94]. Also, as a photosensitizer, when subjected to light irradiation, the resulting photo toxicity prevents microbial growth. A few in vitro studies evaluated PDT with curcumin and reported moderate to strong antimicrobial activity against *Aa*, *Pg*, and *Fn* [32,33,37,95]. However, evidence on the clinical benefits of curcumin PDT as an adjunct to periodontal treatment is scarce [79,96].

Take-Home Message

Findings from in vitro studies suggest that curcumin has the ability to promote osteogenesis, downregulate proteases, promote wound healing, and suppress periodontal bacteria. Findings from animal studies suggest the enormous potential of curcumin and its derivatives to contribute to mechanical periodontal treatment, as experimental inflammation and alveolar bone loss show remarkable reduction after curcumin treatment.

Despite the high number of clinical studies on the use of curcumin in periodontology, there are several missing points before curcumin can become part of the traditional treatment approach. The low toxicity, limited side effects, availability, low cost, and a full spectrum of beneficial biological properties are among the main advantages of curcumin. Results from most clinical trials suggest that the benefits of curcumin and CMC are at least comparable to CHX, but with fewer side effects and higher patient acceptance. In gingivitis, the use of mouthwash seems to provide the most efficient delivery of curcumin, whereas in periodontitis, the use of curcumin gel has been the most studied form. Currently, adjunctive PDT with curcumin does not seem to provide additional benefits to SRP, however, it can be beneficial in the treatment of smokers and patients who have systemic disease. Additional studies are warranted to shed light on substantivity, formulations, delivery, and doses. Curcumin analogs seem to present superior outcomes due to increased bioavailability and potency. For wound healing, the use of curcumin strips and gel shows good potential and should be further explored. Although still in its infancy, the use of membranes containing curcumin can open new possibilities for tissue regeneration in the future.

The anti-plaque, antioxidant and anti-inflammatory properties of curcumin are remarkable, however, the lack of robust scientific studies with larger samples and longer follow-ups currently hinders its clinical application. While the majority of pre-clinical and clinical studies on periodontal disease have investigated the topical application of curcumin, its potential to improve the host response when used

as a nutritional supplement should not be ignored despite.

Conclusion

Curcumin, an ancient natural remedy and spice, has been extensively studied for its wide spectrum of health benefits, mainly related to the anti-microbial, anti-inflammatory, anti-oxidant, and anti-cancer properties. In periodontology, the benefits of curcumin topical use have been compared to those of chlorhexidine due to its potential to combat plaque, modulate the host response, decrease periodontal inflammation, and alveolar bone loss. Those properties have been widely confirmed in pre-clinical studies. The majority of clinical studies on the adjunctive use of curcumin in periodontal disease report superior clinical and microbiological results when compared to mechanical therapy alone. Nonetheless, there is a lack of randomized clinical trials with long-term follow-up and adequate sample size. Despite the major health benefits associated with systemic supplementation with curcumin, more studies are warranted in order to investigate its effectiveness in the management of periodontal disease. Lastly, curcumin analogs have improved the chemical structure of this polyphenol to improve its biological activity; however, its clinical application requires further scientific investigation.

References

1. Prasad S, Aggarwal BB. (2011) Turmeric, the golden spice: From traditional medicine to modern medicine. In: Herbal Medicine: Biomolecular and Clinical Aspects: Second Edition. CRC Press; pp. 263-88.
2. Schraufstatter E, Bernt H. (1949) Antibacterial action of curcumin and related compounds. *Nature*. 164(4167):456-57.
3. Azuine MA, Bhide SV. (1994) Adjuvant chemoprevention of experimental cancer: catechin and dietary turmeric in forestomach and oral cancer models. *J Ethnopharmacol*. 44(3):211-17.
4. Zhang Y, M Golub L, Johnson F, Wishnia A. (2012) pKa, Zinc- and Serum Albumin-Binding of Curcumin and Two Novel Biologically- Active Chemically-Modified Curcumins. *Curr Med Chem*. 19(25):4367-375.
5. Tang W, Du M, Zhang S. (2020) Therapeutic effect of curcumin on oral diseases: A literature review. *Phyther Res*.
6. Golub LM, Lee HM. (2020) Periodontal therapeutics: Current host-modulation agents and future directions. *Periodontology 2000*. 82(1):186-204.
7. Mills IJ. (2017) A person-centred Approach to holistic Assessment. *Prim Dent J*. 6(3):18-23.
8. Gennings C, Ellis R, Ritter JK. (2012) Linking empirical estimates of body burden of environmental chemicals and wellness using NHANES data. *Environ Int*. 39(1):56-65.
9. Yeung AWK, Horbanczuk M, Tzvetkov NT, Mocan A, Carradori S, et al. (2019) Curcumin: Total-Scale Analysis of the Scientific Literature. *Mol*. 24(7):1393.
10. Pulido-Moran M, Moreno-Fernandez J, Ramirez-Tortosa C. (2016) Curcumin and health. *Mol*. 21(3):264.
11. Lelli D, Sahebkar A, Johnston TP, Pedone C. (2017) Curcumin use in pulmonary diseases: State of the art and future perspectives. *Pharmacol Res*. 115:133-148.
12. Kwiecien S, Magierowski M, Majka J, Belowska AP, Wojcik D, et al. (2019) Curcumin: A potent protectant against esophageal and gastric disorders. *Int J Mol Sci*. 20(6):1477.
13. Bhat A, Mahalakshmi AM, Ray B, Tuladhar S, Hediya TA, et al. [2019] Benefits of curcumin in brain disorders. *Bio Factors*. 45(5):666-89.
14. Farzaei MH, Zobeiri M, Parvizi F, El-Senduny FF, Marmouzi I, Coy-Barrera E, et al. (2018) Curcumin in liver diseases: A systematic review of the cellular mechanisms of oxidative stress and clinical perspective.

- Nutrients. 10(7):855.
15. Li H, Sureda A, Devkota HP, Pittala V, Barreca D, et al. [2020] Curcumin, the golden spice in treating cardiovascular diseases. *Biotechnol Adv.* 38:107343.
 16. Giordano A, Tommonaro G. [2019] Curcumin and cancer. *Nutrients.* 11(10):2376.
 17. Vollono L, Falconi M, Gaziano R, Iacovelli F, Dika E, et al. [2019] Potential of Curcumin in Skin Disorders. *Nutrients* 9:2169.
 18. Tayyem RF, Heath DD, Al-Delaimy WK, Rock CL. [2006] Curcumin content of turmeric and curry powders. *Nutr Cancer.* 55:126-31.
 19. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. [2007] Bioavailability of curcumin: Problems and promises. *Mol Pharm.* 4(6):807-18.
 20. Stohs SJ, Chen O, Ray SD, et al. [2020] Highly Bioavailable Forms of Curcumin and Promising Avenues for Curcumin-Based Research and Application: A Review. *Mol.* 25(6):1397.
 21. Borges JS, Paranhos LR, de Souza GL, de Souza Matos F, de Macedo Bernardino I, et al. [2020] Does systemic oral administration of curcumin effectively reduce alveolar bone loss associated with periodontal disease? A systematic review and meta. *J Funct Foods.* 75:104226.
 22. Dei Cas M, Ghidoni R. [2019] Dietary curcumin: Correlation between bioavailability and health potential. *Nutrients.* 11(9):2147.
 23. [2017] Hewlings S, Kalman D. Curcumin: A Review of Its Effects on Human Health. *Foods.* 6:92.
 24. [2014] Refined exposure assessment for curcumin (E 100). *EFSA J.* 12(10):3876.
 25. Lao CD, Ruffin IV MT, Normolle D, Heath DD, Murray SI, et al. [2006] Dose escalation of a curcuminoid formulation. *BMC Complement Altern Med.* 6(1):1-4.
 26. Elburki MS, Rossa C, Guimaraes MR, Goodenough M, Lee HM, et al. [2014] A novel chemically modified curcumin reduces severity of experimental periodontal disease in rats: Initial observations. *Mediators Inflamm.*
 27. Xiong Y, Zhao B, Zhang W, Jia L, Zhang Y, et al. [2020] Curcumin promotes osteogenic differentiation of periodontal ligament stem cells through the PI3K/AKT/Nrf2 signaling pathway. *Iran J Basic Med Sci.* 23:954-60.
 28. Bosca AB, Ilea A, Soritau O, Tatomir C, Miklasova N, et al. [2019] Modulatory effect of curcumin analogs on the activation of metalloproteinases in human periodontal stem cells. *Eur J Oral Sci.* 127(4):304-12.
 29. Sukumaran S, Vadakkekuttical R, Kanakath H. [2020] Comparative evaluation of the effect of curcumin and chlorhexidine on human fibroblast viability and migration: An in vitro study. *J Indian Soc Periodontol.* 24:109-16.
 30. Guru SR, Kothiwale SV, Saroch N, Guru RC. [2017] Comparative evaluation of inhibitory effect of curcumin and doxycycline on matrix metalloproteinase-9 activity in chronic periodontitis. *Indian J Dent Res.* 28(5):560-65.
 31. Izui S, Sekine S, Maeda K, Kuboniwa M, Takada A, et al. [2016] Antibacterial Activity of Curcumin Against Periodontopathic Bacteria. *J Periodontol.* 87(1):83-90.
 32. Najafi S, Khayamzadeh M, Paknejad M, Poursepanj G, Fard MJ, et al. [2016] An in vitro comparison of antimicrobial effects of curcumin-based photodynamic therapy and chlorhexidine, on *Aggregatibacter actinomycetemcomitans*. *J Lasers Med Sci.* 7:21-5.
 33. Saitawee D, Teerakapong A, Morales NP, Jitprasertwong P, Hormdee D. [2018] Photodynamic therapy of *Curcuma longa* extract stimulated with blue light against *Aggregatibacter actinomycetemcomitans*. *Photodiagnosis Photodyn Ther.* 22:101-05.
 34. Sha AM, Garib BT. [2019] Antibacterial Effect of Curcumin against Clinically Isolated *Porphyromonas gingivalis* and Connective Tissue Reactions to Curcumin Gel in the Subcutaneous Tissue of Rats. *Biomed Res Int.*

35. Kumbar VM, Peram MR, Kugaji MS, Shah T, Patil SP, et al. [2020]. Effect of curcumin on growth, biofilm formation and virulence factor gene expression of *Porphyromonas gingivalis*. *Odontology*.
36. de Paula Zago LH, de Annunzio SR, de Oliveira KT, Barbugli PA, Valdes BR, et al. [2020] Antimicrobial photodynamic therapy against metronidazole-resistant dental plaque bacteria. *J Photochem Photobiol B Biol*. 209.
37. Pan H, Wang D, Zhang F. [2020] In vitro antimicrobial effect of curcumin-based photodynamic therapy on *Porphyromonas gingivalis* and *Aggregatibacter actinomycetemcomitans*. *Photodiagnosis Photodyn Ther*. 32:102055.
38. Shahzad M, Millhouse E, Culshaw S, Edwards CA, Ramage G, et al. [2015] Selected dietary (poly)phenols inhibit periodontal pathogen growth and biofilm formation. *Food Funct*. 6(3):719-29.
39. Chen D, Nie M, Fan MW, Bian Z. [2008] Anti-inflammatory activity of curcumin in macrophages stimulated by lipopolysaccharides from *Porphyromonas gingivalis*. *Pharmacol*. 82(4):264-69.
40. Hu P, Huang P, Chen MW. [2013] Curcumin attenuates cyclooxygenase-2 expression via inhibition of the NF- κ b pathway in lipopolysaccharide-stimulated human gingival fibroblasts. *Cell Biol Int*. 37:443-48.
41. Akpınar A, Calisir M, Karakan NC, Alpan AL, Goze F, et al. [2017] Effects of curcumin on alveolar bone loss in experimental periodontitis in rats: A morphometric and histopathologic study. *Int J Vitam Nutr Res*. 87:262-70.
42. Bakır B, Yetkin Ay Z, Buyukbayram HI, Kumbul Doguc D, Bayram D, et al. [2016] Effect of Curcumin on Systemic T Helper 17 Cell Response; Gingival Expressions of Interleukin-17 and Retinoic Acid Receptor-Related Orphan Receptor γ t; and Alveolar Bone Loss in Experimental Periodontitis. *J Periodontol*. 87:e183-e191.
43. Xiao CJ, Yu XJ, Xie JL, Liu S, Li S. [2018] Protective effect and related mechanisms of curcumin in rat experimental periodontitis. *Head Face Med*. 14(1):1-8.
44. Zhou T, Chen D, Li Q, Sun X, Song Y, et al. [2013] Curcumin inhibits inflammatory response and bone loss during experimental periodontitis in rats. *Acta Odontologica Scandinavica*. 71:349-56.
45. Ay ZY, Bakır B, Bozkurt ŞB, Kayis SA, Hakki SS. [2020] Positive effect of curcumin on experimental periodontitis via suppression of IL-1-beta and IL-6 expression level. *Int J Vitam Nutr Res*.
46. Deng J, Golub LM, Lee HM, Lin MC, Bhatt HD, et al. [2020] Chemically-modified curcumin 2.24: A novel systemic therapy for natural periodontitis in dogs. *J Exp Pharmacol*. 12:47-60.
47. Guimaraes-Stabili MR, de Aquino SG, de Almeida Curylofo F, Tasso CO, Rocha FR, et al. [2019] Systemic administration of curcumin or piperine enhances the periodontal repair: a preliminary study in rats. *Clin Oral Investig*. 23(8):3297-3306.
48. Zambrano LM, Brandao DA, Rocha FR, Marsiglio RP, Longo IB, et al. [2018] Local administration of curcumin-loaded nanoparticles effectively inhibits inflammation and bone resorption associated with experimental periodontal disease. *Sci Rep*. 8(1):1-1.
49. Theodoro LH, Ferro-Alves ML, Longo M, Nuernberg MA, Ferreira RP, et al. [2017] Curcumin photodynamic effect in the treatment of the induced periodontitis in rats. *Lasers Med Sci*. 32:1783-91.
50. Correa MG, Pires PR, Ribeiro FV, Pimentel SZ, Casarin RC, et al. [2017] Systemic treatment with resveratrol and/or curcumin reduces the progression of experimental periodontitis in rats. *J Periodontol Res*. 52:201-9.
51. Pimentel SP, Casati MZ, Ribeiro FV, Correa MG, Franck FC, et al. [2020] Impact of natural curcumin on the progression of experimental periodontitis in diabetic rats. *J Periodontol Res*. 55(1):41-50.
52. de Almeida Brandao D, Spolidorio LC, Johnson F, Golub LM, Guimaraes-Stabili MR, et al. [2019] Dose-response assessment of chemically modified curcumin in experimental periodontitis. *J Periodontol*. 90(5):535-45.
53. Elburki MS, Moore DD, Terezakis NG, Zhang Y, Lee HM, et al. [2017] A novel chemically modified curcumin

- reduces inflammation-mediated connective tissue breakdown in a rat model of diabetes: periodontal and systemic effects. *J Periodontal Res.* 52(2):186-200.
54. Elburki MS, Rossa C, Guimaraes-Stabili MR, Lee HM, Curylofo-Zotti FA, et al. [2017] A Chemically Modified Curcumin (CMC 2.24) Inhibits Nuclear Factor κ B Activation and Inflammatory Bone Loss in Murine Models of LPS-Induced Experimental Periodontitis and Diabetes-Associated Natural Periodontitis. *Inflammation.* 40(4):1436-49.
 55. Guimaraes MR, Coimbra LS, De Aquino SG, Spolidorio LC, Kirkwood KL, et al. [2011] Potent anti-inflammatory effects of systemically administered curcumin modulate periodontal disease in vivo. *J Periodontal Res.* 46:269-79.
 56. Mau LP, Cheng WC, Chen JK, Shieh YS, Cochran DL, et al. [2016] Curcumin ameliorates alveolar bone destruction of experimental periodontitis by modulating osteoclast differentiation, Activation and function. *J Funct Foods.* 22:243-56.
 57. Wang HH, Lee HM, Raja V, Hou W, Iacono VJ, et al. [2019] Enhanced efficacy of chemically modified curcumin in experimental periodontitis: systemic implication. *J Exp Pharmacol.* 11:1-14.
 58. Curylofo-Zotti FA, Elburki MS, Oliveira PA, Cerri PS, Santos LA, et al. [2018] Differential effects of natural Curcumin and chemically modified curcumin on inflammation and bone resorption in model of experimental periodontitis. *Arch Oral Biol.* 91:42-50.
 59. Ay ZY, Bakir B, Bozkurt SB, Kayis SA, Hakki SS. [2020] Positive effect of curcumin on experimental periodontitis via suppression of IL-1-beta and IL-6 expression level. *Int J Vitam Nutr Res.*
 60. Hosadurga RR, Rao SN, Jose J, Rompicharla NC, Shakil M, et al. [2014] Evaluation of the efficacy of 2% curcumin gel in the treatment of experimental periodontitis. *Pharmacognosy Res.* 6(4):326.
 61. Ghavimi MA, Shahabadi AB, Jarolmasjed S, Memar MY, Dizaj SM, et al. [2020] Nanofibrous asymmetric collagen/curcumin membrane containing aspirin-loaded PLGA nanoparticles for guided bone regeneration. *Sci Rep.* 10(1):1-5.
 62. Singh V, Pathak AK, Pal M, Sareen S, Goel K. [2015] Comparative evaluation of topical application of turmeric gel and 0.2% chlorhexidine gluconate gel in prevention of gingivitis. *Natl J Maxillofac Surg.* 6(1):67.
 63. Kandwal A, Mamgain R, Mamgain P. [2015] Comparative evaluation of turmeric gel with 2% chlorhexidine gluconate gel for treatment of plaque induced gingivitis: A randomized controlled clinical trial. *AYU (An Int Q J Res Ayurveda).* 36(2):145.
 64. Pulikkotil SJ, Nath S. [2015] Effects of curcumin on crevicular levels of IL-1 β and CCL28 in experimental gingivitis. *Aust Dent J.* 60(3):317-27.
 65. Behal R, Mali AM, Gilda SS, Paradkar AR. [2011] Evaluation of local drug-delivery system containing 2% whole turmeric gel used as an adjunct to scaling and root planing in chronic periodontitis: A clinical and microbiological study. *J Indian Soc Periodontol.* 15(1):35-8.
 66. Kaur H, Grover V, Malhotra R, Gupta M. [2018] Evaluation of curcumin gel as adjunct to scaling & root planing in management of periodontitis- Randomized clinical & biochemical investigation. *Infect Disord Drug Targets.* 19(2):171-8.
 67. Siddharth M, Singh P, Gupta R, Sinha A, Shree S, et al. [2020] A Comparative Evaluation of Subgingivally Delivered 2% Curcumin and 0.2% Chlorhexidine Gel Adjunctive to Scaling and Root Planing in Chronic Periodontitis. *J Contemp Dent Pract.* 21(5):494-99.
 68. Jaswal R, Dhawan S, Grover V, Malhotra R. [2014] Comparative evaluation of single application of 2% whole turmeric gel versus 1% chlorhexidine gel in chronic periodontitis patients: A pilot study. *J Indian Soc Periodontol.* 18(5):575.
 69. Meghana MV, Deshmukh J, Devarathanamma MV, Asif K, Jyothi L, et al. [2020] Comparison of effect of curcumin gel and noneugenol periodontal dressing in tissue response, early wound healing, and pain

- assessment following periodontal flap surgery in chronic periodontitis patients. *J Indian Soc Periodontol.* 24(1):54-59.
70. Sreedhar A, Sarkar I, Rajan P, Pai J, Malagi S, et al. [2015] Comparative evaluation of the efficacy of curcumin gel with and without photo activation as an adjunct to scaling and root planing in the treatment of chronic periodontitis: A split mouth clinical and microbiological study. *J Nat Sci Biol Med.* 6(Suppl 1):S102.
 71. Mohammad CA. [2020] Efficacy of curcumin gel on zinc, magnesium, copper, IL-1 β , and TNF- α in chronic periodontitis patients. *Biomed Res Int.*
 72. Chatterjee A, Debnath K, Rao NKH. [2017] A comparative evaluation of the efficacy of curcumin and chlorhexidine mouthrinses on clinical inflammatory parameters of gingivitis: A double-blinded randomized controlled clinical study. *J Indian Soc Periodontol.* 21:132-37.
 73. Mali A, Behal R, Gilda S. [2012] Comparative evaluation of 0.1% turmeric mouthwash with 0.2% chlorhexidine gluconate in prevention of plaque and gingivitis: A clinical and microbiological study. *J Indian Soc Periodontol.* 16(3):386.
 74. Muglikar S, Patil KC, Shivswami S, Hegde R. [2013] Efficacy of curcumin in the treatment of chronic gingivitis: A pilot study. *Oral Health Prev Dent.* 11(1):81-816.
 75. Arunachalam LT, Sudhakar U, Vasanth J, Khumukchum S, Selvam VV. [2018] Comparison of anti-plaque and anti-gingivitis effect of curcumin and chlorhexidine mouth rinse in the treatment of gingivitis: A clinical and biochemical study. *J Indian Soc Periodontol.* 21(6):478.
 76. Anusha D, Chaly PE, Junaid M, Nijesh JE, Shivashankar K, et al. [2019] Efficacy of a mouthwash containing essential oils and curcumin as an adjunct to nonsurgical periodontal therapy among rheumatoid arthritis patients with chronic periodontitis: A randomized controlled trial. *Indian J Dent Res.* 30(4):506-11.
 77. Gottumukkala SN, Koneru S, Mannem S, Mandalapu N. [2013] Effectiveness of sub gingival irrigation of an indigenous 1% curcumin solution on clinical and microbiological parameters in chronic periodontitis patients: A pilot randomized clinical trial. *Contemp Clin Dent.* 4:186.
 78. Perez-Pacheco CG, Fernandes NA, Primo FL, Tedesco AC, Bellile E, et al. [2020] Local application of curcumin-loaded nanoparticles as an adjunct to scaling and root planing in periodontitis: Randomized, placebo-controlled, double-blind split-mouth clinical trial. *Clin Oral Investig.* 30:1-1.
 79. Ivanaga CA, Miessi DM, Nuernberg MA, Claudio MM, Garcia VG, et al. [2019] Antimicrobial photodynamic therapy (aPDT) with curcumin and LED, as an enhancement to scaling and root planing in the treatment of residual pockets in diabetic patients: A randomized and controlled split-mouth clinical trial. *Photodiagnosis Photodyn Ther.* 27:388-95.
 80. Anil A, Gujjari SK, Venkatesh MP. [2019] Evaluation of a curcumin-containing mucoadhesive film for periodontal postsurgical pain control. *J Indian Soc Periodontol.* 23:461-68.
 81. Gottumukkala SN, Sudarshan S, Mantena SR. [2014] Comparative evaluation of the efficacy of two controlled release devices: Chlorhexidine chips and indigenous curcumin based collagen as local drug delivery systems. *Contemp Clin Dent.* 5:175-181.
 82. Singh A, Sridhar R, Shrihatti R, Mandloy A. [2018] Evaluation of Turmeric Chip Compared with Chlorhexidine Chip as a Local Drug Delivery Agent in the Treatment of Chronic Periodontitis: A Split Mouth Randomized Controlled Clinical Trial. *J Altern Complement Med.* 24:76-84.
 83. Malekzadeh M, Kia SJ, Mashaei L, Moosavi MS. [2020] Oral nano-curcumin on gingival inflammation in patients with gingivitis and mild periodontitis. *Clin Exp Dent Res.*
 84. Kaur S, Sharma R, Sarangal V, Kaur N, Prashar P. [2017] Evaluation of anti-inflammatory effects of systemically administered curcumin lycopene and piperine as an adjunct to scaling and root planing: A clinical study. *AYU (An Int Q J Res Ayurveda).* 38:117.
 85. Singh S, Aggarwal BB. [1995] Activation of transcription factor NF- κ B is suppressed by curcumin

- (diferulolylmethane). *J Biol Chem.* 270(42):24995-5000.
86. Livada R, Shiloah J, Tipton DA, Dabbous MK. The Potential Role of Curcumin in Periodontal Therapy: A Review of the Literature. *J Int Acad Periodontol.* 19(3):70-9.
 87. Hong J, Bose M, Ju J, Ryu JH, Chen X, et al. [2004] Modulation of arachidonic acid metabolism by curcumin and related β -diketone derivatives: Effects on cytosolic phospholipase A2, cyclooxygenases and 5-lipoxygenase. *Carcinogenesis.* 25(9):1671-79.
 88. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, et al. [2001] Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: Down-regulation of COX-2 and iNOS through suppression of NF- κ B activation. *Mutat Res- Fundam Mol Mech Mutagen.* 480:243-68.
 89. Ben P, Liu J, Lu C, Xu Y, Xin Y, et al. [2011] Curcumin promotes degradation of inducible nitric oxide synthase and suppresses its enzyme activity in RAW 264.7 cells. *Int Immunopharmacol.* 11(2):179-86.
 90. Mantovani A, Bussolino F, Introna M. [1997] Cytokine regulation of endothelial cell function: From molecular level to the bedside. *Immunology Today.* 18(5):231-5.
 91. Kim DC, Lee W, Bae JS. [2011] Vascular anti-inflammatory effects of curcumin on HMGB1-mediated responses in vitro. *Inflamm Res.* 60(12):1161-8.
 92. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. [2006] Multiple biological activities of curcumin: A short review. In: *Life Sciences.* Pergamon. 78(18):2081-7.
 93. Dinkova-Kostova AT, Talalay P. [2008] Direct and indirect antioxidant properties of inducers of cytoprotective proteins. *Mol Nutr Food Res.* 52(S1):S128-38.
 94. Zheng D, Huang C, Huang H, Zhao Y, Khan MR, et al. [2020] Antibacterial Mechanism of Curcumin: A Review. *Chem Biodivers.* 17(8):e2000171.
 95. Mahdi Z, Habiboallah G, Mahbobeh NN, Mina ZJ, Majid Z, et al. [2015] Lethal effect of blue light-activated hydrogen peroxide, curcumin and erythrosine as potential oral photosensitizers on the viability of *porphyromonas gingivalis* and *fusobacterium nucleatum*. *Laser Ther.* 24:(2):103-11.
 96. Sreedhar A, Sarkar I, Rajan P, Pai J, Malagi S, et al. [2015] Comparative evaluation of the efficacy of curcumin gel with and without photo activation as an adjunct to scaling and root planing in the treatment of chronic periodontitis: A split mouth clinical and microbiological study. *J Nat Sci Biol Med.* 6:S102-S109.